Neuvotion was founded by Chad Bouton, a professor at the Feinstein Institutes for Medical Research at Northwell Health. The startup plans to use the funding to grow its staff, complete clinical trials, and get FDA clearance for its first product.
“Neuvotion’s noninvasive AI-based technology has the potential to revolutionize rehabilitation for patients who are suffering from movement impairment,” said Milind Parate, who leads Northwell Holdings‘ ventures portfolio, in an April 13 news release. “We look forward to supporting the work of the Neuvotion team as they develop this novel technology and assess its efficacy in addressing this significant challenge.”
The early-stage company plans to start a multisite clinical study this year.
